<DOC>
	<DOCNO>NCT01601834</DOCNO>
	<brief_summary>The purpose study healthy people evaluate safety , toleration time course plasma concentration single oral dos PF-06273340 . The effect food Pharmacokinetic PF-06273340 may also investigate .</brief_summary>
	<brief_title>A First In Human Study In Healthy People To Evaluate Safety , Toleration And Time Course Of Plasma Concentration Of Single Oral Doses Of PF-06273340</brief_title>
	<detailed_description />
	<criteria>Healthy male subject female subject nonchild bear potential age 18 55 year , inclusive . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . An informed consent document sign date subject Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption ( e.g. , gastrectomy ) . A positive urine drug screen . History regular alcohol consumption exceed 14 drinks/week female 21 drinks/week male ( 1 drink = 5 ounce ( 150 mL ) wine 12 ounce ( 360 mL ) beer 1.5 ounce ( 45 mL ) hard liquor ) within 6 month screen . Treatment investigational drug within 30 day ( determined local requirement , whichever long ) 5 halflives precede first dose study medication . Screening supine blood pressure &gt; = 140 mm Hg ( systolic ) &gt; = 90 mm Hg ( diastolic ) , single measurement ( confirm single repeat , necessary ) follow least 5 minute rest . 12lead ECG demonstrate QTc &gt; 450 msec screening . If QTc exceed 450 msec , ECG repeat two time average three QTc value use determine subject 's eligibility . Females child bear potential . Use prescription nonprescription drug dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication . Herbal supplement must discontinue 28 day prior first dose study medication . As exception , acetaminophen/paracetamol may use dos 1 g/day . Limited use nonprescription medication believe affect subject safety overall result study may permit casebycase basis follow approval sponsor . Blood donation approximately 1 pint ( 500 mL ) within 56 day prior dose . History sensitivity heparin heparininduced thrombocytopenia . Unwilling unable comply Lifestyle guideline describe protocol . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Single Dose</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>Toleration</keyword>
</DOC>